Can-Fite(CANF) - 2021 Q4 - Annual Report

Exhibit 99.1 Can-Fite Reports 2021 Financial Results & Provides Clinical Update · Cash balance of $18.9 million as of December 31, 2021 · Signed out-licensing deal worth $42.7 million with Ewopharma · Phase III psoriasis topline data expected Q2 2022 · Namodenoson induced complete response and cleared all cancer lesions in advanced liver cancer patient in Can-Fite's Phase II study · Phase IIb NASH study is currently enrolling patients · Pivotal Phase III advanced liver cancer study expected to commence enro ...